Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and maximum tolerated dose (MTD) of carfilzomib in combination with
lenalidomide and dexamethasone in patients with relapsed multiple myeloma